Era of direct acting anti-viral agents for the treatment of hepatitis C

Table 7 Recommended and alternative therapy

Genotype	Treatment-naïve and - experienced patients with HCV infection in the allograft without cirrhosis	Treatment-naïve and - experienced patients with HCV infection in the allograft with compensated cirrhosis	Treatment-naïve and - experienced patients with HCV infection in the allograft with decompensated cirrhosis
Recommended therapy
1, 4, 5 or 6	Glecaprevir/Pibrentasvir (Mavyret) - 12 wk or Ledipasvir/Sofosbuvir (Harvoni) for 12 wk	Ledipasvir/Sofosbuvir (Harvoni) with weight-based ribavirin - 12 wk	Ledipasvir/Sofosbuvir (Harvoni) with initial low dose of ribavirin (600 mg), increase the dose as tolerated - 12 wk
2 or 3	Glecaprevir/Pibrentasvir (Mavyret) - 12 wk or Daclatasvir (Daklinza) plus Sofosbuvir (Sovaldi) with initial low dose of ribavirin (600 mg), increase the dose as tolerated for 12 wk	Daclatasvir (Daklinza) plus Sofosbuvir (Sovaldi) with initial low dose of ribavirin (600 mg), increase the dose as tolerated - 12 wk	Daclatasvir (Daklinza) plus Sofosbuvir (Sovaldi) with initial low dose of ribavirin (600 mg), increase the dose as tolerated for 12 wk or Sofosbuvir/Velpatasvir (Epclusa) with weight-based ribavirin - 12 wk
Alternative therapy
1, 4, 5 or 6	Daclatasvir (Daklinza) plus Sofosbuvir (Sovaldi) with initial low dose of ribavirin (600 mg), increase the dose as tolerated for 12 wk or HCV genotype 1 or 4 infection only: Simeprevir (Olysio) plus Sofosbuvir (Sovaldi) with or without weight-based ribavirin	Daclatasvir (Daklinza) plus Sofosbuvir (Sovaldi) with initial low dose of ribavirin (600 mg), increase the dose as tolerated for 12 wk or HCV genotype 1 or 4 infection only: Simeprevir (Olysio) plus Sofosbuvir (Sovaldi) with or without weight-based ribavirin
2 or 3		Glecaprevir/Pibrentasvir (Mavyret) for 12 wk or Sofosbuvir/Velpatasvir (Epclusa) with weight-based ribavirin for 12 wk

HCV: Hepatitis C virus.